Related by context. All words. (Click for frequent words.) 63 riociguat 62 chromium supplementation 61 renoprotective 61 Known hypersensitivity 60 midstage clinical 60 MAGE A3 ASCI 60 Vlachopoulos 60 Per Olof Wallström 60 PROCHYMAL 60 Perforomist ™ Inhalation Solution 59 MGN# 59 selenium supplementation 59 antioxidant supplementation 59 Nicole Onetto MD 59 statins cholesterol lowering 59 William Sandborn MD 59 SUTENT ® 59 Dr. Ayalew Tefferi 59 lymphomas leukemias 58 balsalazide tablet 58 acetonide FA 58 fibrate drugs 58 Quyyumi 58 HuMax EGFr 58 developmental neurotoxicity 58 immunomodulatory properties 58 Removab 58 neratinib 58 preclinically 58 Gheorghiade 58 Dr. Pasinetti 58 Okunieff 57 ASSERT trial 57 INSPIRE Trial Phase III 57 beta carotene supplementation 57 Egrifta 57 Teriflunomide 57 CHARM Added 57 poststroke depression 57 BEXXAR Therapeutic Regimen 57 ThermoDox ® clinical 57 Subgroup analysis 57 meta analysis pooling 57 Dr. Roehrborn 57 MGd 57 antiresorptive 57 Lipid lowering 57 oral picoplatin 57 preclinical pharmacokinetic 57 Wayne Katon 57 amifostine 57 containing LABAs 57 ACCORD Eye 57 antiangiogenic therapy 57 Laheru 57 TransVax tm 57 Mark A. Sirgo 57 atacicept 57 brivaracetam 57 triglyceride lowering 57 Urocortin 2 57 Georges Gemayel 57 Mr. Rosconi 57 journal Gynecologic Oncology 57 Hertzel Gerstein 57 tumor hypoxia 57 Bresalier 57 Joseph Loscalzo 57 antioxidant vitamin supplements 57 relapsed MM 56 Dr. Sosne 56 Dr. Relkin 56 phase IIIb 56 vascular thrombosis 56 PROactive study 56 confirmatory clinical 56 MERLIN TIMI 56 number NCT# ClinicalTrials.gov 56 CaPre TM 56 tramiprosate Alzhemed TM 56 efaproxiral 56 preclinical pharmacology 56 Bruce Psaty 56 Dr. Fehlings 56 chemoprotective 56 NP2 Enkephalin 56 eritoran 56 Kandzari 56 Coumadin warfarin 56 NSAID induced GI 56 sorafenib Nexavar 56 Kamada AAT 56 CARE HF 56 Avandia Actos 56 eprotirome 56 dietary carotenoids 56 Cochrane reviewers 56 CA9 SCAN 56 Lopid 56 Aprotinin 56 ZOLINZA 56 induced hepatotoxicity 56 thorough QT 56 Vincent Cogliano 56 HQK 56 Phase III ADT 56 probiotic supplementation 56 SILENOR 56 alemtuzumab MS 56 OvaRex MAb 56 Iris Loew Friedrich 56 Vidaza azacitidine 56 Panzem R NCD 56 SPARCL 56 Steve Worland Ph.D. 56 BrachySil TM 56 Dr. Gulfo 56 Afatinib 56 enzastaurin 56 impair fertility 56 Regulatory Toxicology 56 Patricia Hartge 56 Dal Pan 56 Cristofanilli 56 LibiGel ® 56 cardioprotective effects 56 Mr. Mordock 56 Arranon 56 prospective nonrandomized 56 immune modulating 56 gallium nitrate 56 CINQUIL 56 Steven R. Deitcher 56 EEG abnormalities 55 Warfarin Coumadin 55 barbiturates benzodiazepines 55 clevidipine 55 Plaquenil 55 ADVANCE PD 55 APEX AMI 55 teratogenicity 55 Dickersin 55 PSMA ADC 55 impaired insulin secretion 55 pharmacologic stress 55 Dr. Montori 55 Daniel Junius 55 prospective multicentre 55 kidney urologic 55 RE LY trial 55 Demark Wahnefried 55 metaanalysis 55 topical NSAIDs 55 YONDELIS 55 Aplidin 55 subchronic 55 conjugated estrogen 55 Bergenstal 55 adenosine A2A 55 Aldara Cream 55 mTOR inhibition 55 Xcytrin R 55 antifibrinolytic 55 axitinib 55 Exherin TM 55 erlotinib Tarceva 55 Phase IIIB IV 55 hepatotoxic 55 HMG CoA reductase inhibitors 55 antiangiogenic agents 55 PROCRIT ® 55 CRLX# 55 samalizumab 55 pharmacokinetics pharmacodynamics 55 Chimowitz 55 noscapine 55 randomized controlled clinical trials 55 Zyprexa LAI 55 demonstrated antitumor activity 55 tubulin inhibitor 55 CURE AF 55 biologic pathways 55 myopathy rhabdomyolysis 55 Darinaparsin 55 Serebruany 55 Dr. Kauvar 55 Cardiotoxicity 55 Lorianne Masuoka MD 55 oral salmon calcitonin 55 Phase IIIb study 55 Inflammatory diseases 55 Loretta M. Itri 55 testosterone supplementation 55 Hans Joachim Lohrisch 55 Wilmanns 55 J. Donald deBethizy 55 Shark cartilage 55 Panzem 55 Singh Manoux 55 Zemplar Capsules 55 DCCR 55 LAB CGRP 55 JAK inhibitor 55 AChE inhibitors 55 Amir Lerman 55 flavopiridol 55 RhuDex 55 multicenter Phase II 55 known sulfonamide allergy 55 Aflibercept 55 Onrigin 55 Cariprazine 55 ADVEXIN therapy 55 Michael Leitzmann 55 Allovectin 7 ® 55 dose proportionality 55 Darapladib 55 REMINYL ® 55 NATRECOR ® 55 SNT-MC#/idebenone 55 journal Carcinogenesis 55 Aviptadil 55 INTEGRILIN R eptifibatide Injection 55 thromboembolic disease 55 Shlipak 54 Tsimikas 54 antitumor effect 54 eprodisate Fibrillex TM 54 JoAnn Manson 54 paroxetine sertraline 54 metabonomics 54 inhalation powder 54 Sudhir Agrawal D.Phil 54 torcetrapib atorvastatin 54 inecalcitol 54 pharmacodynamic markers 54 cMET 54 HDL Selective Delipidation 54 potassium sparing 54 thalidomide Thalomid 54 Aggrastat ® tirofiban hydrochloride 54 Eric Van Cutsem 54 soy isoflavone 54 Cardiorespiratory fitness 54 Aggressive Reduction 54 olaparib 54 lumiliximab 54 STRIDE PD 54 CYP#D# inhibitor 54 Commonly prescribed 54 rThrombin 54 Abbott Trilipix 54 Dr. Maraganore 54 PLX STROKE targeting 54 MediGene focuses 54 Colin Baigent 54 labetalol 54 dose escalation phase 54 MYTHOS trial 54 BCIRG 54 Histopathological 54 Ateronon 54 Triapine R 54 alvespimycin 54 pharmacodynamic effects 54 adalimumab Humira 54 rheumatoid arthritis osteoarthritis ankylosing 54 Navas Acien 54 Canvaxin 54 Steven Galson MD MPH 54 Marc Weisskopf 54 Alton Boynton 54 CaPSURE 54 pharmacokinetic PK study 54 plasma pharmacokinetics 54 Tasigna prolongs 54 Tumor Response 54 phase Ib 54 ongoing Phase IIIb 54 deforolimus 54 Liprotamase 54 antineoplastic 54 preclinical efficacy 54 ULTRAM ER 54 Cholesterol lowering statins 54 biostatistical analysis 54 palifermin 54 cannabinor 54 Carbamazepine 54 Dr. Gussak 54 Safi Bahcall Ph.D. 54 Dr. Coppari 54 Aclidinium 54 Alvesco R 54 basal bolus regimen 54 anticholinergic agents 54 SNT MC# 54 epigenetic therapies 54 Ana Navas Acien 54 pentoxifylline 54 teriflunomide 54 NUCYNTA ™ 54 prostate carcinogenesis 54 cardiotoxic 54 SE5 OH containing 54 INVEGA ® SUSTENNA ® 54 HOPE TOO 54 NIASPAN 54 plasma kallikrein inhibitor 54 Flavanols 54 ARBITER 6 54 Vaccine Immunology 54 dietary acrylamide 54 anti androgens 54 ASCEND HF 54 CLDs 54 Pi Sunyer 54 Phase 1a clinical 54 J. Mazzo Ph.D. 54 Undesirable alterations 54 NeuroVax 54 GFT# 54 huC# DM4 54 teratogenic effects 54 pathogenetic mechanisms 54 Rachel Ballard Barbash 54 indibulin 53 Michael Fonstein Ph.D. 53 isoflavone supplements 53 phase IIa clinical 53 thiazide 53 Paliperidone ER 53 abnormal liver enzymes 53 AVERROES 53 Molecular Cancer 53 Kevetrin ™ 53 bovine thrombin 53 inhaled AAT 53 gabapentin Neurontin 53 Myfortic 53 Tony Wyss Coray 53 Werner Hacke 53 vismodegib 53 blood clot dissolving 53 Alequel 53 Francesca Bravi 53 pharmacokinetic pharmacodynamic 53 pharmacokinetic characteristics 53 Fibrillex TM 53 intensive statin therapy 53 Alan Dangour 53 stratifying patients 53 Vertos II 53 Ismail Beigi 53 Mr. Yves Rosconi 53 oral rivaroxaban 53 ALK inhibitors 53 Soy isoflavones 53 EchoCRT 53 radiolabeled TM# 53 TACI Ig 53 antidiabetic drug 53 BIM #A# 53 PEG SN# 53 Elocalcitol 53 Randomized trials 53 pivotal bioequivalence 53 HORIZONS AMI 53 Elisabeth Lindner CEO 53 vildagliptin 53 Lynda Chin 53 follicular adenoma 53 Paul Thornalley 53 GERD migraine headaches 53 anticholesterol 53 KAPVAY ™ 53 CIMZIA TM certolizumab pegol 53 Vitaxin 53 SomatoKine 53 EECP ® therapy 53 Mitchell Krucoff 53 somatostatin analogues 53 Bengt Winblad 53 zileuton IV 53 Mihael Polymeropoulos MD 53 Certolizumab pegol 53 prospectively stratified 53 Subgroup analyzes 53 Monique MB Breteler 53 Trofex 53 glatiramer 53 biodistribution studies 53 intravenous bisphosphonates 53 Michael H. Tardugno 53 relapsed MCL 53 Actimmune ® 53 Dr. Arndt Schottelius 53 Cholesterol Levels SPARCL 53 pharmacokinetic interactions 53 Cascade LifeSciences 53 Lipoic acid 53 biologic DMARDs 53 Zeb Horowitz 53 asymptomatic hyperuricemia 53 dermatologic diseases 53 Rik J Deitsch 53 antiplatelet medications 53 inhibit metastasis 53 Giulio Maria Pasinetti 53 Dr. Chodick 53 G. biloba 53 journal Arteriosclerosis Thrombosis 53 Phase 1b trial 53 Proellex TM 53 Pischon 53 EP #R 53 Heavy snorers 53 FASLODEX 53 untreated OSA 53 Rigorous scientific 53 Fanconi syndrome 53 Joshua Boger Ph.D. 53 Edward Giovannucci 53 Roche Xeloda 53 fusion enhancers 53 COX inhibitors 53 renal toxicity 53 HIV HCV coinfected 53 urocortin 2 53 Carl A. Pelzel 53 ACCORD Lipid 53 Cancidas 53 lowering triglyceride levels 53 Kurella Tamura 53 mechanistic studies 53 torsemide ER 53 intermittent dosing 53 E. Magnus Ohman 53 successfully commercialize Iluvien 53 HF ACTION 53 EMBEDA ™ 53 Phase IIb III 53 herpes zoster vaccine 53 Dr. Borlongan 53 Amarenco 53 KRAS status 53 Edwin Hemwall 53 thetreatment 53 GRNCM1 53 Amy Abernethy 53 Prostate Disease 53 DeKosky 53 antiplatelet therapies 53 dacetuzumab 53 AVANDIA 53 BMC Musculoskeletal Disorders 53 hypersensitivity allergic reactions 53 ganetespib 53 anthracycline chemotherapy 53 hepatocellular carcinoma liver 53 chemopreventive agents 53 RSD# oral 53 ONCONASE R 53 TLR antagonists 53 Mayo Clinic hematologist 53 cardiometabolic disorders 53 endothelin antagonists 53 HuLuc# 53 included exfoliative dermatitis 53 HGS# 53 immunotoxicity 53 Michael F. Leitzmann 53 Robert Motzer MD 53 EMPOWER ™ 53 M. Ridker 53 apneic episodes 53 panitumumab Vectibix 53 velafermin 53 Shoelson 53 Dr. Fombonne 53 Steven B. Ratoff 53 Celebrex celecoxib 53 Phase #b/#a 53 erythropoietic 53 tiagabine 53 immuno modulatory 53 budesonide MMX Phase III 53 non resectable metastatic 53 AZILECT R 53 Sanctura XR 53 Seroquel quetiapine 53 antiarrhythmic 53 Joseph K. Belanoff 53 RIO Lipids 53 Lancet Oncology journal 53 statin medications 52 biologic plausibility 52 Sackner Bernstein 52 Screening Trial DMIST 52 Tony Milici 52 FOR FURTHER INFORMATION ABOUT 52 APPROVe trial 52 Oparil 52 Beatrice Golomb 52 prospective observational studies 52 Hedgehog antagonist 52 hepatic toxicity 52 immunotherapeutic approaches 52 SinuNase ™ 52 pharmacogenetic testing 52 ExTRACT TIMI 52 gemifloxacin 52 EndoTAGTM 1 52 Nicholas Borys 52 coinfected patients 52 journal Pharmacotherapy 52 EnVivo 52 tryptase 52 Duromist ™ 52 DSMB recommended 52 UPLYSO 52 squamous cell lung cancer 52 Metabolism Excretion 52 Robert L. Bratzler 52 toxicologic 52 Mevacor lovastatin 52 darbepoetin alfa Aranesp 52 Giuseppe Fortuni 52 Deutsches Arzteblatt International 52 ocrelizumab 52 hoFH patients 52 adrenal suppression 52 canakinumab 52 Lovastatin 52 ELACYT 52 CONBRIZA 52 FRAGMIN R 52 intracranial stenosis 52 cancerous colon polyps 52 rindopepimut 52 potassium sparing diuretics 52 staphylococcal vaccine 52 BRIM3 52 immunosuppressant therapy 52 ICON7 52 Navelbine R 52 aclidinium bromide 52 AZILECT ® 52 cancer chemoprevention 52 postmarketing adverse 52 Current Author Addresses 52 Vernakalant 52 antidiabetic drugs 52 blinded randomized placebo controlled 52 Anthony Giovinazzo 52 meta regression 52 HNRCA 52 REACH Registry 52 Oral corticosteroids 52 ergot alkaloids 52 ICD therapy 52 Yvonne Greenstreet 52 pharmacodynamic parameters 52 Starlix 52 1mg 2mg 52 Viprinex TM 52 compound INCB# 52 bladder ovarian 52 Dr. Eugene Braunwald 52 Noxafil 52 ImmunoCellular Therapeutics 52 cardiopulmonary bypass surgery 52 journal Chemical Senses 52 Pharmacokinetic studies 52 postoperative chemotherapy 52 dextromethorphan DM 52 Dr. Eliaz 52 florbetaben 52 Anavex #-# 52 acute bronchospasm 52 Zemplar 52 PDE# inhibitors 52 Shamay Tsoory 52 trastuzumab DM1 52 AERx iDMS 52 Patrik De Haes 52 Barbara Alving 52 lipoprotein profiles 52 Drew Fromkin President 52 EMPOWER TM 52 Dr. LaMattina 52 Markus Heilig 52 spirometric 52 Edge STudy 52 Aciphex R 52 de Werf 52 rates Tangka 52 nonsteroidal 52 Silodosin 52 Dan Passeri Curis 52 dermatologic reactions 52 pharmacoeconomic analysis 52 noncancer 52 VADT 52 NCCN guidelines 52 Zevalin consolidation 52 Gurbel 52 Regranex 52 buprenorphine implants 52 postoperative pulmonary 52 Oglemilast 52 oral methylnaltrexone 52 NPWH 52 HYVET 52 INVEGA ™ 52 Avastin adjuvant 52 Myriad Flurizan 52 Dr. Fonstein 52 Dr. Cliby 52 Clinical Antipsychotic Trials 52 Dr. Gozal 52 Allovectin 7 52 Targretin capsules 52 antiepileptics 52 liver metastasis 52 Christos Mantzoros 52 Serdolect ® 52 griseofulvin 52 forodesine 52 PREVENT IV 52 mu opioid agonists 52 Hotamisligil 52 isoflavone supplement 52 Bisphosphonate 52 Amplimexon 52 antithrombotic therapy 52 Sebivo 52 Zonszein 52 masitinib 52 methylation biomarkers 52 Intervention Trial GAIT 52 farletuzumab 52 ipratropium bromide 52 Phase IIB 52 ImmunoVEX HSV2 52 CCR9 antagonist 52 periodically reassessed 52 renal denervation 52 heterozygous FH 52 Dr. Julie Buring 52 inhaled bronchodilators 52 EXPLORE Xa 52 Winkelmayer 52 journal Behavioral Neuroscience 52 Dialysis Outcomes 52 HCV protease inhibitors 52 Michele Garufi Chairman 52 Roxana Mehran MD 52 Nonclinical 52 ASK DR 52 Symadex 52 postmarket surveillance 52 vidofludimus 52 ADCIRCA 52 Phase 2b RESTORE CLI 52 piroxicam 52 NV1FGF 52 Elevated triglycerides 52 ziconotide 52 non steroidals 52 Arikace 52 Jon Kar Zubieta 52 ALB # 52 Topiramate 52 drug eluting stent implantation 52 Tschöp 52 cocoa flavonoids 52 Capoten 52 EXJADE 52 adipiplon 52 Potiga 52 longitudinal cohort 52 Carotid Revascularization Endarterectomy vs. 52 ethyl mesilate 52 insulin secretagogues 52 cerebral microbleeds 52 ADME properties 52 Neil K. Warma 52 Dr. Zelenetz 52 BoNTA 52 retrospective observational 52 genomic biomarkers 52 Tomas Puusepp 52 Prestara 52 ONTARGET 52 Blum Cytokinetics 52 nonpharmacologic 51 Toxicological Sciences 51 journal Toxicological Sciences 51 GRAVITAS trial 51 OpenNotes 51 adrenocortical cancer 51 lomitapide 51 Kevetrin TM 51 APEX PD 51 CaPre ™ 51 Kiadis Pharma 51 Fred Kavalier 51 Zavesca r 51 intranasal corticosteroids 51 Dr. Randall Yatscoff 51 OvaRex 51 Dacogen injection 51 diagnosing ADHD 51 OvaRex R 51 Lancet Neurology journal 51 Qi Dai 51 AA Amyloidosis 51 antifibrotic 51 carotid plaque 51 George Ebers 51 Chemophase 51 systemic hypotension 51 Sol J. Barer 51 Kimmie Ng 51 antiplatelet drugs 51 infantile colic 51 NATRECOR R 51 midstage trials 51 oral ridaforolimus 51 Genz # 51 BARI 2D 51 skin sterol 51 NINR 51 Fx #A 51 Kalantar Zadeh 51 neural degeneration 51 zileuton CR 51 Nordestgaard 51 BGC# 51 chemoprevention trials 51 Lawrence Cheskin 51 IMA# 51 BEXXAR therapeutic regimen 51 Laura Mauri 51 Tobias Kurth 51 Schernhammer 51 opioid naive 51 antiinflammatory drugs 51 journal Anticancer 51 Dr. McHutchison 51 Antioxidant supplements 51 James Sapirstein 51 incyclinide 51 Kuppermann 51 Coadministration 51 QVAR 51 PreCISe 51 BLA filing 51 Dr. Whitcup 51 topical calcineurin inhibitors 51 Ridker 51 Lipid Lowering Treatment 51 Mr. Bentsur 51 Dr. Aiping Young 51 VTE prevention 51 journal Circulation Cardiovascular 51 Alfred I. Neugut 51 Kuvan sapropterin dihydrochloride 51 AVN# Phase 51 EDEMA3 trial 51 ovarian endometrial 51 neuropsychiatric events 51 Gurian Sherman 51 AppTec acquisition 51 Iodine counteracts 51 journal Nature Reviews 51 Ph.D MPH 51 STEP BD 51 pharmacokinetic studies 51 aerosolized surfactant 51 methodologically rigorous 51 CALGB 51 PROSTVAC TM 51 pharmacokinetic parameters 51 guggul 51 PFO migraine 51 Auxilium Pharma 51 Soffritti 51 multicenter trials 51 Observational studies 51 hypervascular tumors 51 Dr. Gurbel 51 opioid mediated 51 Stephanie Belloc 51 pharmacologically relevant 51 Cinquil 51 Confirmatory tests 51 Elisabeth Cardis 51 Matthew Meyerson 51 Howard H. Pien 51 Vectibix monotherapy 51 serum phosphorous 51 CTAP# Capsules 51 Val HeFT 51 Mark HN Corrigan 51 leukotriene receptor antagonists 51 KIACTA ™ 51 eTag assays 51 CAMPATH 51 papillary renal cell carcinoma 51 Arno Therapeutics 51 Lixivaptan 51 AMEVIVE 51 PRIMO CABG 51 Vectibix panitumumab 51 Pedro Lichtinger 51 CMV vaccine 51 Azathioprine 51 Pseudomonas aeruginosa infections 51 Dr. Michelle Berrey 51 Frobell 51 Mechanistic studies 51 Thiovir 51 nanoparticle toxicity 51 AZD# TC 51 Smeyne 51 DHA supplementation 51 serum GGT 51 PRTX 51 buccal tablets 51 Mayo Clinic oncologist 51 Randomized controlled 51 BYETTA exenatide injection 51 teratogenic 51 Lewis Cantley 51 hawthorn extract 51 Crestor Lipitor 51 DSMB recommendation 51 non ulcer dyspepsia 51 DNAwithPap TM Test 51 Phase III metastatic melanoma 51 Virulizin ® 51 Hematide ™ 51 postmarketing surveillance 51 CINOD 51 Remicade infliximab 51 eltrombopag 51 elotuzumab 51 antinausea 51 CHAMPION PCI 51 indications contraindications 51 NicOx commented 51 Pimavanserin 51 hematological parameters 51 GAMMAGARD 51 Phase Ib II 51 nalbuphine ER 51 macitentan 51 stimulant ADHD 51 Ovbiagele 51 cardiac toxicity 51 Symbicort asthma 51 ProSavin 51 Daniel Passeri Curis 51 methylxanthines 51 severe hypersensitivity reactions 51 Wactawski Wende 51 Teplizumab 51 neuroprotective properties 51 Prof. Krainer 51 Nissen meta analysis 51 USL# 51 SIMPONI ® 51 PLAC test 51 topical formulations 51 SinuNase TM 51 Wassertheil Smoller 51 Dr. Philip Toleikis 51 APPRAISE 51 thromboxane A2 51 containing drospirenone 51 Catherine DeAngelis 51 inhalation toxicity 51 Dr. Bezprozvanny 51 biomarker identification 51 BioVant 51 Hakon Hakonarson 51 PhosLo 51 Salmeterol 51 statins Diabetology Asthma 51 desipramine 51 Ascherio 51 Thorough QT 51 LibiGel ® testosterone gel 51 Polyunsaturated fat 51 H2 blocker 51 PNH patients 51 PNT# 51 journal Epilepsia 51 journal Langmuir 51 acute phosphate nephropathy 51 MEK inhibitor RDEA# 51 TASKi2 51 CombAT study 51 Asentar 51 Artificial pancreas 51 Logical Therapeutics 51 itraconazole Sporanox 51 antirheumatic 51 Phase #b/#a clinical 51 carotid atherosclerosis 51 Kristine Yaffe MD 51 Taxotere chemotherapy 51 dietary antioxidants 51 subcutaneous PRO 51 antiemetics 51 Hypertensive adverse reactions 51 ototoxic 51 non cirrhotic portal 51 tolevamer 51 CAMMS# 51 oncological outcomes 51 Dr. Henrich Guntermann 51 Tardive dyskinesia 51 PANVAC VF 51 mycophenolate mofetil 51 Paxil paroxetine 51 Eunyoung Cho 51 Lu AA# 51 Anat Cohen Dayag 51 John C. Ruckdeschel 51 Dr. Hakon Hakonarson 51 HMGCR 51 astemizole 51 acid ethyl esters 51 Marc Oczachowski 51 Dr. Bruno Giannetti 51 Ele Ferrannini 51 oral antidiabetes 51 lipid lowering therapies 51 journal Pharmacoepidemiology 51 surveys Herbenick 51 Dr. Yatscoff 51 treat enlarged prostate 51 PRESEPT 51 Limbrel 51 AdreView 51 trastuzumab DM1 T DM1 51 PXD# 51 ThromboGenics commenting 51 Quay MD Ph.D. 51 Phase #/#a 51 ularitide 51 CURRENT OASIS 7 51 placebo controlled clinical 51 breast carcinogenesis 50 AAEM 50 James Manuso 50 INTEGRILIN 50 Guillermo Torre Amione 50 Kritchevsky 50 OvaRex ® MAb 50 Tovaxin TM 50 silent ischemia 50 deCODE AF TM 50 Evoltra ® 50 Dr. Draelos 50 Dino Dina 50 journal Cephalalgia 50 liprotamase 50 CYT# potent vascular disrupting 50 blood thinner Warfarin 50 Epidemiologic studies 50 venous thromboembolic disease 50 Dr. Raafat Fahim 50 bevirimat Study 50 Luigi Ferrucci 50 Lactobacillus GG 50 pretransplant 50 genomic biomarker 50 KRAS gene mutations 50 eculizumab therapy 50 Reefhuis 50 Pegloticase 50 pharmacokinetic interaction 50 journal Ophthalmology 50 clomipramine 50 Randomised controlled trials 50 elevated homocysteine 50 ß blockers 50 bazedoxifene conjugated estrogens 50 Weese Mayer 50 Ophena TM 50 fasting lipid 50 gastric corpus 50 JAK inhibitors 50 Alzhemed TM 50 cardio metabolic